Friday, 23 May 2014

Type 2 diabetes: European Commission approves Jardiance® (empagliflozin) tablets for use in adults in Europe

European Commission approves third product from the Boehringer Ingelheim and Lilly Diabetes alliance


Plasma advanced glycation endproducts are associated with incident cardiovascular events in individuals with type 2 diabetes: a case-cohort study with a median follow-up of 10 years (EPIC-NL)

high plasma AGEs were associated with incident cardiovascular events in individuals with T2DM. These results underline the potential importance of AGEs in development of CVD (Diabetes)

No comments:

Post a Comment